Section Arrow
LGND.NASDAQ
- Ligand Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/16 15:31 EST
Regular Hours
Last
 200.86
-0.41 (-0.20%)
Day High 
205.32 
Prev. Close
201.27 
1-M High
212.49 
Volume 
132.27K 
Bid
183.4
Ask
299
Day Low
198.515 
Open
198.93 
1-M Low
177.76 
Market Cap 
3.96B 
Currency USD 
P/E 88.67 
%Yield -- 
10-SMA 199.8 
20-SMA 193.06 
50-SMA 181.28 
52-W High 212.49 
52-W Low 93.58 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.27/6.41
Enterprise Value
3.97B
Balance Sheet
Book Value Per Share
48.28
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
167.13M
Operating Revenue Per Share
9.14
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 15:31 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license andmilestone payments, and sale of its trademarked Captisol material.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.